Daligdig, Chantel .
HRN: 15-54-50 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/21/2023
05/25/2023
IV
150mg
Q24
PCAP C
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes